भारतीय इम्युनोलॉजिकल्स लिमिटेड, हैदराबाद (आईआईएल)

National Dairy Development Board (NDDB) established Indian Immunologicals Ltd. (IIL) in 1982 with the objective of making Foot and Mouth Disease (FMD) vaccine available to farmers at an affordable price. The technology for FMD vaccine manufacture was obtained from M/s. Wellcome Foundation, UK. The plant in Hyderabad today has a capacity to make 360 million trivalent doses of FMD vaccine, making it the largest producer of this vaccine in the world.

IIL is the largest veterinary biological company in India with a range of vaccines for cattle, sheep and canine segments. Combined with its presence in the formulations segment, IIL holds the third position in the Indian animal health market. IIL is also a major player in the human vaccine market in India focusing on the pediatric vaccine and rabies vaccine segments. IIL holds the third position in this market.

IIL established Human Biologicals Institute (HBI) in 1999 to manufacture modern Tissue Culture Anti Rabies Vaccine (TCARV) for human use at Ooty, Tamilnadu. Based on the capacity created by IIL, the Government was able to phase out usage of NTV from Government hospitals. IIL is now the largest producer and supplier of the human rabies vaccine with a capacity of nearly 10 mio. doses per annum.

In 2003, HBI established facilities in Hyderabad for producing vaccines for the Universal Immunization Programme (UIP) such as DPT, TT, DT, Hepatitis–B and Measles vaccines. The facility was inaugurated by the former President Dr APJ Abdul Kalam. IIL is on the verge of obtaining manufacturing license of other human vaccines such as the combination DPT and Hib (quadrivalent) vaccine, the combination DPT, Hib and Hepatitis B (Pentavalent) vaccine and the Hepatitis-A vaccine.

The Research and Development team at IIL has been working on new generation technologies to develop new vaccines such as an oral Human Papilloma virus vaccine, Recombinant Dengue Vaccine, Japanese Encephalitis Vaccine, Typhoid vaccine, Hepatitis-A vaccine and Monoclonal antibodies against a number of diseases.

IIL has now built a new animal health formulations facility outside Hyderabad in Biotech Park – Phase II at Karkapatla. This is the largest such Formulations plant for the animal health market in India. This site also houses new manufacturing facility for human rabies vaccine.

IIL operates an animal nutrition and feed plant in Rajkot, Gujarat, which manufactures standard and specialized cattle feed, feed for laboratory animals and a range of animal nutrition products. These products are targeted at improving productivity of livestock in India through better nutrition.

In FY 2014-15, IIL posted sales revenues of 4830 mio. IIL employs about 1200 people.

IIL pursues not only the mandate of NDDB to provide products and services to enhance the quality of livestock in the country, but also uses its technological capabilities for the benefit of the people of India. IIL strongly believes that its mission of "biotechnology in healthcare made affordable and accessible" can be actively pursued only with sound technology base in modern biotechnology.